Abstract:There is a critical unmet need for therapeutics to treat the epidemic of comorbidities associated with obesity and type 2 diabetes, ideally devoid of nausea/emesis. This study developed monomeric peptide agonists of glucagon-like peptide 1 receptor (GLP-1R) and neuropeptide Y2 receptor (Y2-R) based on exendin-4 (Ex-4) and PYY3–36. A novel peptide, GEP44, was obtained via in vitro receptor screens, insulin secretion in islets, stability assays, and in vivo rat and shrew studies of glucoregulation, weight loss, nausea, and emesis. GEP44 in lean and diet-induced obese rats produced greater reduction in body weight compared to Ex-4 without triggering nausea associated behavior. Studies in the shrew demonstrated a near absence of emesis for GEP44 in contrast to Ex-4. Collectively, these data demonstrate that targeting GLP-1R and Y2-R with chimeric single peptides offers a route to new glucoregulatory treatments that are well-tolerated and have improved weight loss when compared directly to Ex-4.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01783?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01783</a>.Structure of GLP-1R 310L (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01783/suppl_file/jm0c01783_si_001.pdb">PDB</a>)In vitro dose–response curves, summary of PEP-FOLD3 structural modeling, HPEPDOCK molecular docking peptide–receptor simulations, ESMS and RP-HPLC purity traces, dose–response nonlinear regression, in vivo studies, pooled rat liver microsome assays, body weight data from a longitudinal study assessing glucose tolerance, dose escalation experiments, and stratification factors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01783/suppl_file/jm0c01783_si_002.pdf">PDF</a>)Structure of Y2-R 21K3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01783/suppl_file/jm0c01783_si_003.pdb">PDB</a>)Raw PYMOL docking data(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01783/suppl_file/jm0c01783_si_004.zip">ZIP</a>)This article has not yet been cited by other publications.

NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?

Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes

An update on peptide-based therapies for type 2 diabetes and obesity

Does GIPR blockade as well as agonism have a role to play in management of obesity and diabetes?

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

GLP-1 and PYY for the treatment of obesity: use of agonists and antagonists in diet-induced rats, a pilot study

Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis

Evolution of peptide YY analogs for the management of type 2 diabetes and obesity

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

Designer GLP1 poly-agonist peptides in the management of diabesity

GLP-1 and Amylin in the Treatment of Obesity

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3-36 in the suppression of food, drug-seeking, and anxiogenesis